SEC Comment Letter 0000000000-24-009654 to CASI Pharmaceuticals, Inc. (CASI) (CIK 0001962738) (CASIF)
CASI Pharmaceuticals, Inc. (CASI) (CIK 0001962738)
Date: Aug. 23, 2024 · CIK: 0001962738 · Accession: 0000000000-24-009654
AI Filing Summary & Sentiment
File numbers found in text: 333-281621
Letter
August 23, 2024 Wei-Wu He Chief Executive Officer CASI Pharmaceuticals, Inc. 9620 Medical Center Drive, Suite 300 Rockville, MD 20850 Re:CASI Pharmaceuticals, Inc. Registration Statement on Form F-3 Filed August 16, 2024 File No. 333-281621 Dear Wei-Wu He: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Yuting Wu, Esq.
Show Raw Text
August 23, 2024
Wei-Wu He
Chief Executive Officer
CASI Pharmaceuticals, Inc.
9620 Medical Center Drive, Suite 300
Rockville, MD 20850
Re:CASI Pharmaceuticals, Inc.
Registration Statement on Form F-3
Filed August 16, 2024
File No. 333-281621
Dear Wei-Wu He:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Yuting Wu, Esq.